<DOC>
	<DOCNO>NCT00468546</DOCNO>
	<brief_summary>This study ass safety efficacy rituximab combine MTX participant active rheumatoid arthritis ( RA ) inadequate response anti-Tumor Necrosis ( TNF ) alpha therapy . The anticipated time study 2 year target sample size 500 participant . Eligible participant may receive re-treatment rituximab separate protocol WA17531 .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy MabThera ( Rituximab ) Combination With Methotrexate ( MTX ) Participants With Active Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor Alpha Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult participant 1880 year age active RA least 6 month ; Received treatment RA outpatient basis experience inadequate response intolerance treatment least 1 antiTNF alpha therapy ( etanercept , infliximab adalimumab ) ; Must receive MTX minimum 12 week , last 4 week , prior screen stable dose ; Participants swell joint count ( SJC ) tender joint count ( TJC ) least 8 joint screen randomization ; Radiographic evidence least 1 joint definite erosion due RA ; Participants reproductive potential must use reliable contraceptive method . Bone joint surgery within 8 week prior screen joint surgery plan within 24 week randomization ; Class IV functional status RA ; Previous treatment within 6 month intravenous gamma globulin , Prosorba column ; Intraarticular parenteral corticosteroid within 4 week prior screen visit ; With live vaccine within 4 week prior randomization ; Previous treatment rituximab celldepleting therapy ; Concurrent treatment diseasemodifying antirheumatic drug ( except MTX ) antiTNF alfa factor biologic therapy ; History severe allergic anaphylactic reaction humanize murine monoclonal antibody ; Evidence significant uncontrolled concomitant diseases cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine gastrointestinal disorder ; Known contraindication receive rituximab ; Known active bacterial , viral , fungal , mycobacterial infection ; History recurrent significant infection history recurrent bacterial infection ; Primary secondary immunodeficiency ( history , currently active ) ; History cancer , include solid tumor hematologic malignancy ( except basal cell squamous cell carcinoma skin excise cure ) ; Women pregnant breastfeeding ; History alcohol , drug chemical abuse within 6 month prior screen ; Neuropathies neurovasculopathies might interfere pain evaluation ; Participants poor peripheral venous access ; Intolerance contraindication oral intravenous corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>